[et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.6.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]

Lonafarnib Managed Access Program Launched!

Trial participation and travel to Boston no longer required for most children in order to access this treatment.

We are thrilled to announce that the lonafarnib Managed Access Program (MAP) is now up and running. PRF and lonafarnib manufacturer, Eiger BioPharmaceuticals, have worked together to create this Program. The MAP enables eligible children and young adults with Progeria to obtain the drug lonafarnib through their local physicians in countries that allow the MAP to be offered.

View the full PDF below.

[/et_pb_text][et_pb_button button_url=”https://www.progeriaresearch.org/wp-content/uploads/2019/09/2019-Newletter-For-Web.pdf” button_text=”Read More” button_alignment=”center” _builder_version=”4.6.5″ _module_preset=”default” background_layout=”dark” hover_enabled=”0″ sticky_enabled=”0″][/et_pb_button][/et_pb_column][/et_pb_row][/et_pb_section]